# Immutep Ltd
Who / What
Immutep Ltd is a biotechnology company specializing in cancer immunotherapy through the use of LAG3 (Lymphocyte-Activation Gene 3), an immune checkpoint mechanism. The company focuses on developing treatments that enhance the body’s ability to target and destroy cancer cells.
---
Background & History
Immutep Ltd was originally founded as Prima Biomed, with its roots tracing back to CVac, a therapeutic cancer vaccine initiative. In late 2014, the privately held French immunotherapy firm Immutep SA acquired Prima Biotech, rebranding it as Immutep Ltd while retaining its focus on LAG3-based immunotherapies. The company has evolved from early-stage research into a leader in developing targeted cancer treatments leveraging immune system modulation.
---
Why Notable
Immutep’s work in LAG3 immunotherapy holds significant promise for advancing cancer treatment, offering potential alternatives to current checkpoint inhibitors like PD-1/PD-L1 therapies. By targeting the LAG3 pathway, the company aims to improve efficacy and reduce resistance in immunotherapies, making it a key player in the evolving biotech landscape. Its strategic acquisitions and research focus position it as a notable innovator in precision oncology.
---
In the News
As of recent reports, Immutep continues to advance clinical trials for its LAG3-based therapies, positioning itself at the forefront of cancer immunotherapy innovation. The company’s efforts have drawn attention from investors and researchers alike due to its potential to redefine treatment paradigms in oncology, particularly in solid tumors.
---
Key Facts
---
